FDA Approved Products

1,302 products with lifecycle intelligence, competitive pressure scores, and patent timelines.

Type:AllNDABLAANDA
Lifecycle:GrowthPeakLOE ApproachingPost-LOELaunchPre-Launch
Sort:Approval DateNameCompetitive Pressure↓
Active:Lifecycle: PeakClear all
FOTIVDA
tivozanib
Peak
ORAL · CAPSULE
refractory advanced renal cell carcinoma (RCC) following twomore prior systemic therapies
2021
SMNDA
0/100
FULVESTRANT
fulvestrant
Peak
Fresenius Kabi
INTRAMUSCULAR · SOLUTION
2019
NDA
0/100
FUROSCIX
furosemide injection 80 mg/ 10 ml
Peak
SUBCUTANEOUS · SOLUTION
edema in pediatric patients weighing 43 kgabove+2
2022
NDA
0/100
FYARRO
sirolimus
Peak
INTRAVENOUS · POWDER
2021
NDA
0/100
GALAFOLD
migalastat hydrochloride
Peak
Amicus Therapeutics
ORAL · CAPSULE
an amenable galactosidase alpha gene ( GLA ) variant based on in vitro assay data
2018
NDA
0/100
GANZYK-RTU
ganciclovir
Peak
INTRAVENOUS · SOLUTION
2017
SMNDA
0/100
GAVRETO
pralsetinib
Peak
Rigel Pharmaceuticals
ORAL · CAPSULE
2020
SMNDA
0/100
GELNIQUE
oxybutynin chloride
Peak
AbbVie
TRANSDERMAL · GEL
2009
NDA
0/100
GEMTESA
vibegron
Peak
Sumitomo Dainippon Pharma
ORAL · TABLET
2020
NDA
0/100
GENOSYL
nitric oxide
Peak
INHALATION · GAS
oxygenationreduce the need for extracorporeal membrane oxygenation in term+4
2019
NDA
0/100
GENVOYA
elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide
Peak
Gilead Sciences
ORAL · TABLET
2015
NDA
0/100
GIAPREZA
angiotensin ii
Peak
Immuno Technologies
INTRAVENOUS · SOLUTION
2017
NDA
0/100
GIAZO
balsalazide disodium
Peak
Bausch + Lomb
ORAL · TABLET
2012
NDA
0/100
GILENYA
fingolimod hcl
Peak
Novartis
ORAL · CAPSULE
relapsing forms of multiple sclerosis (MS)to include clinically isolated syndrome+4
2010
NDA
0/100
GIMOTI
metoclopramide hydrochloride
Peak
NASAL · SPRAY, METERED
2020
NDA
0/100
GIVLAARI
givosiran sodium
Peak
Alnylam Pharmaceuticals
SUBCUTANEOUS · SOLUTION
2019
RNANDA
0/100
GLOPERBA
colchicine
Peak
ORAL · SOLUTION
gout flares in adultsgout flares in adults ( )
2019
NDA
0/100
GLYXAMBI
empagliflozin and linagliptin
Peak
Boehringer Ingelheim
ORAL · TABLET
2015
SMNDA
0/100
GOCOVRI
amantadine
Peak
Supernus Pharmaceuticals
ORAL · CAPSULE, EXTENDED RELEASE
2017
NDA
0/100
GONITRO
nitroglycerin
Peak
SUBLINGUAL · POWDER
2016
NDA
0/100
GOPRELTO
cocaine hydrochloride
Peak
NASAL · SOLUTION
2017
NDA
0/100
GVOKE HYPOPEN
glucagon injection, solution
Peak
SUBCUTANEOUS · SOLUTION
2019
NDA
0/100
GVOKE KIT
glucagon injection, solution
Peak
SUBCUTANEOUS · SOLUTION
2019
NDA
0/100
GVOKE PFS
glucagon injection, solution
Peak
SUBCUTANEOUS · SOLUTION
2019
NDA
0/100
← PreviousPage 34 of 55Next →